Analytical Data
-
Gene name
HRP-Labeled Alkaline Phosphatase/ALPL
- Application
-
Alternative Names
rHuAlkaline phosphatase, tissue-nonspecific isozyme/ALPL, His; Alkaline Phosphatase; Tissue-Nonspecific Isozyme; AP-TNAP; TNSALP; Alkaline Phosphatase Liver/Bone/Kidney Isozyme; ALPL
-
Species
Human
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05186-1
-
Expression Region
L18-S502
-
Protein Length
Partial
-
Molecular Weight
40-43 kDa,60-65 kDa & 180 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Recombinant Alkaline Phosphatase (ALPL) labeled with horseradish peroxidase (HRP) represents a significant advancement in the field of biochemistry and molecular biology. ALPL is an essential enzyme involved in various physiological processes, including bone mineralization and the regulation of phosphate levels. The study of ALPL has gained attention due to its implications in bone-related diseases and disorders, such as hypophosphatasia and osteoporosis. The fusion with HRP allows for enhanced detection and quantification capabilities in experimental assays, facilitating studies in enzymology, diagnostics, and therapeutic applications. Using HRP labeling not only improves the stability and activity of ALPL but also enables sensitive colorimetric or chemiluminescent detection methods, making it a valuable tool in research and clinical settings. The characterization and optimization of HRP-labeled ALPL have the potential to advance our understanding of its biological functions and lead to new strategies in the treatment of metabolic bone diseases. Furthermore, this recombinant protein can be utilized in various applications, including enzyme-linked immunosorbent assays (ELISAs), where accurate measurement of enzyme activity is crucial for diagnosing health conditions. Thus, the exploration of HRP-labeled ALPL is pivotal for both fundamental research and translational medicine.
